Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totaling 1,344 shares, a drop of 73.0% from the May 31st total of 4,982 shares. Based on an average daily volume of 4,313 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Wednesday, April 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Addex Therapeutics currently has an average rating of “Sell”.

Addex Therapeutics Stock Performance

Shares of NASDAQ ADXN opened at $6.07 on Friday. The company’s fifty day moving average price is $6.66 and its 200 day moving average price is $7.12. Addex Therapeutics has a 1 year low of $5.41 and a 1 year high of $12.05. The company has a market capitalization of $7.47 million, a PE ratio of -1.06 and a beta of 1.48.

Addex Therapeutics (NASDAQ:ADXN) last posted its quarterly earnings data on Thursday, June 25th. The company reported ($1.50) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.